Overview

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Edotreotide